We expand the global oncology landscape by transforming immunologically cold tumors into targetable biologies, unlocking tumor glycans as novel targets to reverse therapeutic resistance in non-responder patient populations
Develop cutting-edge, innovative antitumor therapies that provide novel alternatives for patients with high unmet medical needs
Glycomime occupies a unique niche at the intersection of glycobiology and active immunotherapy, synergizing the opportunities provided by both fields
Tumor glycan mimetic candidates for next-generation cancer immunotherapies. We develop immunoactive antigens that unmasck silent tumor glycans
We offer agnostic compounds that are compatible with any platform, enabling flexible formulation across a wide range of therapeutic modalities.
Valeria Segatori, PhD
Biotechnology and Immunology
Mariano Gabri, PhD
Gycobiology and Tumor Biology
Mateo Peyloubet
Business
Innovative Solutions for a Healthier Future
Glycomime Biotech SAS
Buenos Aires, Argentina